World Sleep Industry ENCYCLOPEDIA

Urinary Melatonin Metabolite Tests

2.2.1

Analyte and physiological meaning

Urinary melatonin metabolite testing usually measures 6-sulfatoxymelatonin, commonly abbreviated aMT6s or 6-SMT. After melatonin is hydroxylated and conjugated mainly by the liver, this principal metabolite is excreted in urine. The result is therefore an indirect, accumulated measure shaped by melatonin production, metabolism, and renal excretion during the collection interval. It is not the instantaneous concentration of melatonin in blood or saliva.

The test can support research on overnight melatonin output and the broad timing of a circadian rhythm, or selected clinical and research assessments. It does not directly measure sleep duration, sleep stages, ability to fall asleep, or sleep quality. A low urinary value is not automatically “melatonin deficiency,” and a high value does not guarantee healthy sleep. The collection design, reference population, and intended use must support the conclusion stated in the report.

First-morning, overnight, and fractionated collections

A first-morning void or pooled overnight urine can estimate aMT6s excretion during the preceding collection interval without interrupting sleep. Results may be expressed as total amount, an hourly excretion rate, or a ratio to creatinine. A single concentration is also affected by dilution. Only a complete record of start and end times, missed voids, total volume, and calculation method shows whether the result represents concentration, excretion rate, or total output over an interval.

To describe a 24-hour rhythm, a protocol can separate daytime, evening, overnight, and next-morning urine and record the time and volume of each void. Each container integrates the interval from the previous bladder emptying to that void, so its time location is inherently an interval rather than a moment. A missed void, a specimen assigned to the wrong bin, or arbitrary pooling can change peak timing, amplitude, and total output and cannot be reliably reconstructed by software afterward.

Collection, transport, and completeness

Instructions should define how to handle the initial bladder emptying, when each interval begins and ends, whether voids are pooled, which container and preservative to use, required cooling, and delivery time. At minimum, labels need identity, date, actual start and end times, and sequence. A forgotten overnight void, toilet paper or cleanser contamination, a dirty container, insufficient volume, uncontrolled temperature, or unexplained missing material must be documented and handled under a prespecified recollection or rejection rule.

Interpretation also requires sleep timing, light exposure, shift work or time-zone travel, caffeine, alcohol, smoking, exercise, acute illness, and medicines and supplements around collection. Exogenous melatonin changes the measured metabolite and should not be interpreted as endogenous secretion. Whether a prescribed drug or supplement should be withheld must be decided by a clinician; a user should not stop treatment merely to obtain a test.

Concentration, creatinine correction, and excretion rate

Random or first-morning samples often use an aMT6s-to-creatinine ratio to reduce the effect of urine dilution, while timed collections can use volume and duration to calculate an excretion rate. Creatinine correction is not a perfect standard: muscle mass, age, sex, diet, strenuous exercise, and kidney function can affect creatinine. In a complete timed collection, using only the ratio may also discard information about total output. The laboratory should state the denominator, unit, and formula.

Repeated nights within one person may be more informative than comparing one result with a broad population range, but age, puberty, pregnancy, liver and kidney function, and illness can change production or excretion. Reference intervals from different laboratories, intervals, and methods are not interchangeable. A reference interval describes a distribution in a named population. It is not a universal diagnostic cutoff for insomnia, a circadian rhythm disorder, or a proposed “melatonin deficiency” condition.

Analytical methods and quality requirements

aMT6s can be measured by enzyme-linked immunoassay, radioimmunoassay, or liquid chromatography–tandem mass spectrometry. Immunoassays can process many samples efficiently, but antibody cross-reactivity, low-concentration performance, reagent lots, and calibration may affect results. Mass spectrometry offers greater molecular selectivity but still requires validation of extraction recovery, matrix effects, isotope-labeled internal standards, detection and quantification limits, linearity, precision, and stability.

The laboratory should use applicable internal and external quality systems and disclose the analyte, method, unit, measurement uncertainty, treatment of results below quantification, and bridging after a lot or method change. Longitudinal comparisons are strongest with the same collection protocol and method. A research-use assay or evidence of analytical accuracy alone cannot support claims that a test diagnoses a sleep disorder or guides treatment without demonstrated clinical validity.

Circadian phase, DLMO, and sleep diagnosis

Serial fractionated urinary aMT6s can estimate rhythm peak and broad timing, but accumulation in the bladder, hepatic metabolism, and urinary elimination smooth and delay the time signal. Its phase precision is therefore lower than the onset of melatonin measured with frequent blood or saliva samples under dim light. A first-morning specimen in particular cannot by itself provide dim-light melatonin onset, an ideal bedtime, or a phase advance or delay accurate to a particular number of minutes.

Assessment of a circadian rhythm sleep-wake disorder also requires the relationship between symptoms and social schedule, sleep diaries, actigraphy, and selected professional phase testing. Insomnia, excessive sleepiness, snoring, and apnea have many causes unrelated to melatonin. Urinary aMT6s does not replace polysomnography, a multiple sleep latency test, sleep respiratory testing, or another targeted examination, and a normal result cannot exclude those disorders.

Influences, action, and privacy

Nighttime light, schedule changes, shift work, jet lag, season, age, and some medicines can alter endogenous melatonin. Abnormal liver metabolism or renal elimination can also change the relationship between a urinary metabolite and pineal secretion. An unexpected result should first prompt review of collection completeness and timing, exogenous melatonin, medicines, and liver and kidney context, with standardized repetition when appropriate—not self-directed changes in melatonin, hypnotics, or light treatment.

Collection time, sleep schedule, medicines, and hormone results are sensitive health and behavioral data. A service should limit purpose and access, state retention, secondary research, commercial sharing, cross-border processing, and deletion limits, and protect labels, logistics, and digital reports. If sleepiness already compromises driving or machinery use, stop the hazardous activity and seek care. Severe altered consciousness, breathing difficulty, or another emergency requires immediate action rather than waiting for a urine result.